Tandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.65), $0.06 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $15.7 million versus the consensus estimate of $14.92 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.